<DOC>
	<DOCNO>NCT02276222</DOCNO>
	<brief_summary>This long-term safety trial 48 week . Eligible subject enter 48-week , open-label treatment period receive one two treatment ( SUN-101 give 50 mcg twice day Spiriva® [ tiotropium ] give 18 mcg day ) .</brief_summary>
	<brief_title>A Long-Term Safety Trial Treatment With Nebulized SUN-101 Patients With COPD</brief_title>
	<detailed_description>This Phase 3 , randomize , open-label , active-controlled , parallel-group , multicenter , long-term safety trial 48 week treatment nebulized SUN-101 use Investigational eFlow® Closed System ( CS ) nebulizer Spiriva approximately 1050 subject chronic obstructive pulmonary disease ( COPD ) accord Global Initiative Chronic Obstructive Lung Disease ( GOLD 2014 ) guideline . Eligible subject enter 48-week , open-label treatment period follow randomization receive one two treatment ( SUN-101 give 50 mcg BID Spiriva® [ tiotropium ] give 18 mcg QD ) . The hypothesis study incidence treatment-emergent adverse event report course 48 week treatment subject randomize SUN-101 numerically similar incidence treatment-emergent adverse event report course 48 week treatment subject randomize Spiriva ( tiotropium ) .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>1 . Male female patient age ≥ 40 year , inclusive . 2 . A clinical diagnosis COPD accord GOLD 2014 guideline . 3 . Current smoker exsmokers least 10 packyear smoke history ( eg , least 1 pack/day 10 year , equivalent ) . 4 . Postbronchodilator ( follow inhalation ipratropium bromide ) FEV1 &lt; 80 % predict normal &gt; 0.7 L Screening ( Visit 1 ) . 5 . Postbronchodilator ( follow inhalation ipratropium bromide ) FEV1/FVC ratio &lt; 0.70 Screening ( Visit 1 ) . 6 . Ability perform reproducible spirometry accord American Thoracic Society ( ATS ) European Respiratory Society ( ERS ) guideline ( 2005 ) . 7 . Subject , female ≤ 65 year age child bear potential , must negative serum pregnancy test Visit 1 . Females childbearing potential must instruct agree avoid pregnancy study must use acceptable method birth control : ) oral contraceptive , intrauterine device ( IUD ) , implantable contraceptive , transdermal injectable contraceptive least 1 month prior enter study continue use throughout study thirty day follow participation ; b ) barrier method contraception , e.g. , condom /or diaphragm spermicide participate study ; and/or c ) abstinence.. 8 . Willing able provide write informed consent . 9 . Willing able attend study visit adhere study assessment procedure . 1 . Severe comorbidities include unstable cardiac pulmonary disease medical condition would , opinion Investigator , preclude subject safely complete require test study , likely result disease progression would require withdrawal subject . 2 . Concomitant clinically significant respiratory disease COPD ( eg , asthma , tuberculosis , bronchiectasis nonspecific pulmonary disease ) . 3 . Recent history COPD exacerbation require hospitalization need increase treatment COPD within 6 week prior Screening ( Visit 1 ) . 4 . Use daily oxygen therapy &gt; 12 hour per day . 5 . Respiratory tract infection within 6 week prior Screening ( Visit 1 ) . 6 . Use systemic steroid within 3 month prior Screening ( Visit 1 ) . 7 . History malignancy organ system , treat untreated within past 5 year , exception localize basal cell carcinoma skin . 8 . Prolonged QTc ( &gt; 450 msec male &gt; 470 msec female ) Screening ( Visit 1 ) , history long QT syndrome . 9 . History clinically significant ongoing bladder outflow obstruction history catheterization relief bladder outflow obstruction within previous 6 month . 10 . History narrow angle glaucoma . 11 . History hypersensitivity intolerance aerosol medication . 12 . Recent documented history ( within previous 3 month ) substance abuse . 13 . Significant psychiatric disease would likely result subject able complete study , opinion Investigator . 14 . Participation another investigational drug study drug receive within 30 day prior Screening ( Visit 1 ) current participation another investigational drug trial , include SUN101 study . 15 . Previously receive SUN101 ( active treatment ; formerly know EP101 ) . 16 . Contraindicated treatment , history reactions/ hypersensitivity anticholinergic agent , beta2 agonist , sympathomimetic amine .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>COPD</keyword>
</DOC>